Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor β

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 4, 2001, Pages 899-908

  Fu, Xiao Long ^a   Huang, Hong ^a   Bentel, Gunilla ^a   Clough, Robert ^a   Jirtle, Randy L ^a   Kong, Feng Ming ^a   Marks, Lawrence B ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

3 dimensional conformal radiotherapy; Lung cancer; Radiation complications; Transforming growth factor

Indexed keywords

HISTOLOGY; IRRADIATION; RADIATION; RADIOTHERAPY; TOXICITY; TUMORS;

FIBROGENIC CYTOKINES; PLEURAL EFFUSIONS;

ONCOLOGY;

TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOGRAM; HUMAN; LUNG CANCER; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RADIATION INJURY; RISK ASSESSMENT;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG NEOPLASMS; MALE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035879570     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01524-3     Document Type: Article

References (51)

1. Primary tumor control after radiotherapy for carcinoma of the bronchus
2. The long term outcome after radical radiotherapy for advanced localized non-small cell carcinoma of the lung
3. Clinical dose-response curves of human malignant epithelial tumors
4. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer; Unusual toxicity and promising early results
5. Hyperfractionated accelerated radiotherapy for non-small cell lung cancer; Clinical phase I/II trial
6. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
7. Is radiation treatment volume a predictor for acute or late effect on pulmonary function?
8. Radiation pneumonitis following combined modality therapy for lung cancer; Analysis of prognostic factors
9. Predicting radiation response
10. Confirmation of dose-volume histograms and normal tissue complication probability calculations to predict pulmonary complications after radiotherapy for lung cancer
11. Evaluation of an objective plan-evaluation model in the three-dimensional treatment of non-small cell lung cancer
12. Physical and biological predictors of changes in whole-lung function following thoracic irradiation
13. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
14. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
15. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis
16. The physical parameters and molecular events associated with radiation-induced lung toxicity
17. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis
18. Changes in plasma TGF-β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis
19. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis
20. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation
21. Regional dose response to pulmonary irradiation using a manual method
22. Incorporation of functional status into dose-volume analysis
23. Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury
24. Elevated plasma TGFβ1 levels in breast cancer patients decrease following removal of the tumor
25. Nonparametric estimations from incomplete observations
26. Lung cancer
27. Pulmonary toxicity
28. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor
29. Transforming growth factor-beta inhibits endothelial cell proliferation
30. Transforming growth factor-β in disease; The dark side of tissue repair
31. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
32. Elevated plasma levels of TGFβ1 in patients with invasive prostate cancer
33. Tumor marker protocols; Plasma transforming growth factor beta, a plasma tumor marker
34. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma
35. Plasma transforming growth factor-b1 in patients with hepatocellular carcinoma; Comparison with chronic liver diseases
36. TGF-β1 binding protein; A component of the large latent complex of TGF-β1 with multiple repeat sequences
37. Redox-mediated activation of latent transforming growth factor-β1
38. Radiation and the lung; A reevaluation of the mechanisms mediating pulmonary injury
39. Normal tissue injury after cancer therapy is a local manifestation of a systemic condition
40. Plasma TGF-β levels during radiotherapy with or without carboplatin predicts pneumonitis in stage III non-small cell lung cancer
41. Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury
42. Radiation pneumonitis as a function of mean lung dose; An analysis of pooled data of 540 patients
43. Age factors relevant to the development of radiation pneumonitis in lung cancer
44. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast and esophagus cancer patients
45. Clinical radiation pneumonitis and radiographic changes after thoracic radiotherapy for lung carcinoma
46. Risk factors of pneumonitis following chemoradiotherapy for lung cancer
47. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer
48. Alterations in pulmonary mRNA encoding procollagens, fibronectin, and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis
49. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis